Xonvea 10 mg/10 mg gastro-resistant tablets

Land: Irland

Språk: engelsk

Kilde: HPRA (Health Products Regulatory Authority)

Kjøp det nå

Last ned Preparatomtale (SPC)
19-02-2020

Aktiv ingrediens:

Doxylamine hydrogen succinate; Pyridoxine hydrochloride

Tilgjengelig fra:

Alliance Pharma (Ireland) Limited

ATC-kode:

R06AA59

INN (International Name):

Doxylamine hydrogen succinate; Pyridoxine hydrochloride

Dosering :

10/10 milligram(s)

Legemiddelform:

Gastro-resistant tablet

Terapeutisk område:

doxylamine, combinations

Autorisasjon status:

Not marketed

Autorisasjon dato:

2019-04-05

Informasjon til brukeren

                                Xonvea PIL IE 002
PACKAGE LEAFLET: INFORMATION FOR THE USER
XONVEA 10 MG/10 MG GASTRO-RESISTANT TABLETS
doxylamine succinate/pyridoxine hydrochloride
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Xonvea is and what it is used for
2.
What you need to know before you take Xonvea
3.
How to take Xonvea
4.
Possible side effects
5.
How to store Xonvea
6.
Contents of the pack and other information
1.
WHAT XONVEA IS AND WHAT IT IS USED FOR
WHAT XONVEA IS
Xonvea contains two medicines (‘active substances’) called:
‘doxylamine succinate’ and ‘pyridoxine
hydrochloride’.

Doxylamine succinate belongs to a group of medicines called
‘antihistamines’.

Pyridoxine hydrochloride is another name for Vitamin B
6
.
WHAT XONVEA IS USED FOR
Xonvea is used in pregnant women, to help stop them feeling sick
(nausea) and being sick (vomiting).
It is used when changes in diet or other non-medicine treatments have
not worked.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE XONVEA
DO NOT TAKE XONVEA IF:

you are allergic to doxylamine succinate or other antihistamines (such
as diphenhydramine),
pyridoxine hydrochloride or any of the other ingredients of this
medicine (listed in section 6)

you are taking medicines for depression called ‘monoamine oxidase
inhibitors’ (MAOIs)
Do not take Xonvea if any of the above apply to you. If you are not
sure, talk to your doctor,
pharmacist or nurse before taking Xonvea.
WARNINGS AND PRECAUTIONS
Talk to your doctor or pharmacist or nurse before
                                
                                Les hele dokumentet
                                
                            

Preparatomtale

                                Health Products Regulatory Authority
18 February 2020
CRN0094ZY
Page 1 of 8
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Xonvea 10 mg/10 mg gastro-resistant tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each gastro-resistant tablet contains 10 mg doxylamine succinate and
10 mg pyridoxine hydrochloride.
Excipient(s) with known effect
Each tablet contains trace amounts of azo colouring agent E129
For the full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Gastro-resistant tablet (tablet)
White, round, film-coated tablet with a pink image of a pregnant woman
on one side.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Xonvea is indicated for the treatment of nausea and vomiting of
pregnancy in women who do not respond to conservative
management.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The recommended starting dose is two tablets at bedtime (Day 1). If
this dose adequately controls symptoms the next day, the
patient can continue taking two tablets at bedtime. However, if
symptoms persist into the afternoon of Day 2, the patient
should continue the usual dose of two tablets at bedtime (Day 2) and
on Day 3 take three tablets (one tablet in the morning
and two tablets at bedtime). If these three tablets do not adequately
control symptoms on Day 3, the patient can take four
tablets starting on Day 4 (one tablet in the morning, one tablet
mid-afternoon and two tablets at bedtime).
The maximum recommended daily dose is four tablets (one in the
morning, one in the mid-afternoon and two at bedtime).
Xonvea should be taken as a daily prescription and not on an as needed
basis. Continued need for Xonvea should be
reassessed as the pregnancy progresses.
To prevent a sudden return of nausea and vomiting of pregnancy
symptoms, a gradual tapering dose of Xonvea is
recommended at the time of discontinuation.
Paediatric population
Xonvea is not indicated for use in children under 18 years of age. The
safety and efficacy of Xonvea has not been established in
that population (see sec
                                
                                Les hele dokumentet